minktherapeutics.com (INKT): Price-to-Projected Revenue Ratio

INKT (MiNK Therapeutics Inc.) - company brandmark

MiNK Therapeutics, Inc. (INKT) maintains high authority within the oncology community, attracting specialized funds. Manufacturing capacities in Massachusetts are supplemented by US-based CDMO plants, while current revenue is based on investments prior to the market launch of its solid tumor therapy. The forward price-to-sales ratio demonstrates capital dynamics, where the 237.60 mark indicates the level of market expectations regarding the company's future sales.

INKT MiNK Therapeutics Inc.: Market Cap to Future Revenue Ratio in the range 11/14/2026 - 11/18/2026

Analytical breakdowns for MiNK Therapeutics, Inc. (INKT)

- stock exchange capitalization data:
Summary company analysis:minktherapeutics.com INKT
Manufactured products of MiNK Therapeutics, Inc

The forward P/S ratio assesses the market value of a business relative to projected sales volume, allowing for the determination of the premium paid for future cash flows. By analyzing the expected price-to-sales ratio, an investor can mitigate the risk of purchasing an overheated asset, which is critical for MiNK Therapeutics, Inc. (INKT), whose capitalization relies on the uniqueness of cell therapy and strict FDA oversight within clinical trials.

Competitor analysis

ImmunityBio Inc - Forward Price-to-Revenue Multiple|Forward P/S Multiple Immunocore Corp IMCR|JANX - Price-to-Projected Revenue Ratio|RCUS (arcusbio.com) - Market Cap to Projected Revenue|Zymeworks Biopharmaceuticals (ZYME) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Tango Pharma (TNGX)|Forward Price-to-Revenue Multiple IOVA|IMTX - Projected Price to Revenue|Forward Price-to-Revenue Multiple XNCR (Xencor Corp)|Price to Expected Revenue Ratio CMPX|Forward P/S Multiple REPL (Replimune)|Forward Price to Sales LYEL|innate-pharma.com - Forward P/S Multiple|Market Cap to Future Revenue Ratio Pyxis Oncology|Compugen Limited (CGEN) - Price-to-Projected Revenue Ratio|IO Biotech, Inc. - Forward Price to Sales|STRO (sutrobio.com) - Forward P/S Multiple|Forward P/S Multiple werewolftx.com|Price-to-Projected Revenue Ratio immixbio.com (IMMX)|ALXO: Future Price to Revenue|Forward P/S Multiple CUE (Cue Biopharma Inc.)|PDS Biotechnology (PDSB) - Market Cap to Future Revenue Ratio|SONN - Price-to-Projected Revenue Ratio|MAIA Biotechnology, Inc. (MAIA) - Forward Price-to-Revenue Multiple|LIMN: Forward P/S Multiple|LAVA Therapeutics N.V. (LVTX) - Forward P/S Multiple|Forward Price-to-Revenue Multiple NXTC|Forward P/S Multiple leaptx.com|Forward P/S Multiple INTS|Market Cap to Expected Sales Ratio Sensei Biotherapeutics, Inc.|Forward P/S Multiple TOVX (Theriva Corp)|Market Cap to Expected Sales Ratio gritstonebio.com (GRTS)|kinetabio.com - Forward P/S Multiple|NexImmune (NEXI) - Forward Price-to-Revenue Multiple|turnstonebio.com (TSBX) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Vaccinex, Inc (VCNX)|Forward Price-to-Revenue Multiple HARP